The Development of Vaccine Against Parasite Infection
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 1157
Special Issue Editor
Interests: immunology; vaccines; tropical diseases; protozoa; helminths; neglected tropical diseases; one health; comparative medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Parasitic infections affect over three billion people worldwide, leading to significant morbidity and mortality. For over 100 years, the mass administration of anti-parasitic drugs, combined with improved vector control and sanitation measures, has significantly reduced infections, leading to improved health outcomes. However, the rising incidence of anti-parasitic medicines and insecticide resistance threaten the effectiveness of these measures. Vaccines have been used to prevent infections and reduce the burden of disease for over 200 years; however, the only antiparasitic vaccine licensed for clinical use is the RTS, S/AS01 malaria. Therefore, there is an urgent to develop vaccines that target parasitic infections. This Special Issue will focus on several factors that affect the development of vaccines for parasitic diseases, including needs assessments, novel vaccine candidates, adjuvant and delivery system technologies that enhance development strategies, and reviews providing an overview of the current status of the field.
Dr. Kathryn M. Jones
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adaptive immune response
- vaccine
- adjuvant
- protozoal
- helminth
- apicomplexan
- delivery systems
- epidemiology
- needs assessment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
